## **Resource Summary Report**

Generated by FDI Lab - SciCrunch.org on Apr 13, 2025

# InVivoMAb anti-mouse Ly6G/Ly6C

RRID:AB\_2819047 Type: Antibody

#### **Proper Citation**

(Bio X Cell Cat# BE0320, RRID:AB\_2819047)

### **Antibody Information**

URL: http://antibodyregistry.org/AB\_2819047

**Proper Citation:** (Bio X Cell Cat# BE0320, RRID:AB\_2819047)

Target Antigen: Ly6G/Ly6C

Host Organism: rat

**Clonality:** monoclonal

**Comments:** Applications: in vivo neutrophil depletion, Immunohistochemistry (paraffin),

Immunohistochemistry (frozen), Immunofluorescence, Flow cytometry

Antibody Name: InVivoMAb anti-mouse Ly6G/Ly6C

**Description:** This monoclonal targets Ly6G/Ly6C

Target Organism: mouse

Clone ID: clone NIMP-R14

**Antibody ID:** AB\_2819047

Vendor: Bio X Cell

Catalog Number: BE0320

Alternative Catalog Numbers: BE0320-1MG, BE0320-25MG, BE0320-5MG, BE0320-

100MG, BE0320-50MG

**Record Creation Time:** 20231110T032545+0000

**Record Last Update:** 20240725T031517+0000

#### **Ratings and Alerts**

No rating or validation information has been found for InVivoMAb anti-mouse Ly6G/Ly6C.

No alerts have been found for InVivoMAb anti-mouse Ly6G/Ly6C.

#### **Data and Source Information**

Source: Antibody Registry

### **Usage and Citation Metrics**

We found 4 mentions in open access literature.

**Listed below are recent publications.** The full list is available at FDI Lab - SciCrunch.org.

Long AW, et al. (2024) Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma. Journal of hematology & oncology, 17(1), 20.

Chang YW, et al. (2023) A CSF-1R-blocking antibody/IL-10 fusion protein increases antitumor immunity by effectuating tumor-resident CD8+ T cells. Cell reports. Medicine, 4(8), 101154.

Mise Y, et al. (2022) Immunosuppressive tumor microenvironment in uterine serous carcinoma via CCL7 signal with myeloid-derived suppressor cells. Carcinogenesis, 43(7), 647.

Park JA, et al. (2021) Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response. Journal of hematology & oncology, 14(1), 142.